Dr. David H. Goddard, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 52
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 602
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
NY license 185657
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
Medical groups
- New York University (6,134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 602
- Services billed
- 43,021
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 20,787 | 219 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,200 | 508 |
| Injection of drug or substance under skin or into muscle | 428 | 224 |
| Insertion of needle into vein for collection of blood sample | 214 | 162 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 142 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 90 | 90 |
| Dxa bone density measurement of hip, pelvis, spine | 62 | 62 |
| Established patient office or other outpatient visit, 20-29 minutes | 62 | 42 |
| Aspiration and/or injection of fluid from large joint | 25 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Brooklyn, NY | 375 |
| Celecoxib Other prescribers in Brooklyn, NY | 184 |
| Methotrexate (methotrexate sodium) Other prescribers in Brooklyn, NY | 155 |
| Tizanidine Hcl Other prescribers in Brooklyn, NY | 136 |
| Lidocaine Other prescribers in Brooklyn, NY | 129 |
| Meloxicam Other prescribers in Brooklyn, NY | 125 |
| Febuxostat Other prescribers in Brooklyn, NY | 97 |
| Clonazepam Other prescribers in Brooklyn, NY | 75 |
| Prolia (denosumab) Other prescribers in Brooklyn, NY | 66 |
| Diclofenac Sodium Other prescribers in Brooklyn, NY | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $222 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $114 |
|---|---|
| Genentech, Inc. | $53.45 |
| Amgen Inc. | $29.57 |
| GlaxoSmithKline, LLC. | $24.68 |
| Food and Beverage | $168 |
|---|---|
| Education | $53.45 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Mar 19, 2025 | Education in-kind | $53.45 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 28 industry-funded studies in 2025, from 15 companies. The companies reported $761,439 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Celgene Corporation - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB SA · Completed · NCT06624228 - An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT05848258 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis
AstraZeneca Pharmaceuticals LP - A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Eli Lilly and Company · Terminated · NCT05516758 - A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or In…
AstraZeneca UK Limited - A phase 2/3, randomized, double-blind, placebo-controlled, parallel-gr
GlaxoSmithKline, LLC. - A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.